Christopher Wright
Director/Board Member bij ALKERMES PLC
Vermogen: 196 772 $ op 31-03-2024
Profiel
Christopher I.
Wright is an Independent Director at Alkermes Plc and the Chief Medical Officer at Ring Therapeutics, Inc. He previously held positions as the SVP-Global Medicines Development & Medical Affairs at Vertex Pharmaceuticals, Inc., the Chief Development Officer & SVP-Global Development at Ironwood Pharmaceuticals, Inc., an Associate Professor at Harvard Medical School, the Chief Medical Officer & Senior Vice President at Axcella Health, Inc., the Chief Medical Officer & Senior Vice President at Cyclerion Therapeutics, Inc., and the Chief Medical Officer at Aavantibio, Inc. Dr. Wright received his undergraduate degree from Harvard University and his doctorate from Vrije Universiteit Amsterdam.
He also holds graduate and doctorate degrees from Harvard Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 07-07-2023 | 7 269 ( 0.00% ) | 196 772 $ | 31-03-2024 |
Actieve functies van Christopher Wright
| Bedrijven | Functie | Begin |
|---|---|---|
| ALKERMES PLC | Director/Board Member | 24-05-2022 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Christopher Wright
| Bedrijven | Functie | Einde |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 26-03-2021 |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Chief Tech/Sci/R&D Officer | - |
| Harvard Medical School | Corporate Officer/Principal | - |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AXCA HEALPAR | Chief Tech/Sci/R&D Officer | - |
Opleiding van Christopher Wright
| Harvard University | Undergraduate Degree |
| Vrije Universiteit Amsterdam | Doctorate Degree |
| Harvard Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| AXCA HEALPAR | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| ALKERMES PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
